GleamWall
中文EN

AURA Aura Biosciences, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1501796 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-28.6%
TTM EPS YoY16.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-61.7%
ROA-53.5%
ROIC (approx.)-64.7%
Asset turnover—

Leverage & solvency

Liabilities / assets10.6%
Debt / equity0.00x
Current ratio14.21x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.80x
Accruals ratio-10.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$24.74M$30.75M$27.96M$21.90M$22.18M$22.88M$23.34M$22.33M
SG&A expense$10.32M$17.32M$6.91M$5.34M$5.73M$5.73M$5.69M$5.47M
Operating income-$35.06M-$48.07M-$34.87M-$27.24M-$27.91M-$28.61M-$29.04M-$27.81M
Pretax income-$32.03M-$45.61M-$33.67M-$25.54M-$26.10M-$26.97M-$27.46M-$25.81M
Income tax$38,000$29,000$11,000$15,000$26,000$48,000$18,000$24,000
Net income-$32.07M-$45.64M-$33.69M-$25.56M-$26.13M-$27.02M-$27.48M-$25.83M
EBITDA-$34.76M-$47.77M-$34.59M-$26.96M-$27.61M-$28.31M-$28.74M-$27.52M
EPS (basic)-0.29-0.48-0.50—-0.40-0.47-0.55—
EPS (diluted)-0.29-0.48-0.50—-0.40-0.47-0.55—
Weighted avg. shares (diluted)111.07M94.86M67.45M—65.94M58.02M50.13M—
Balance sheet
Cash & equivalents$41.67M$67.84M$84.79M$59.52M$47.55M$107.37M$38.23M$31.69M
Current assets$303.10M$329.03M$118.50M$149.74M$170.12M$183.96M$134.52M$160.62M
PP&E, net$2.02M$2.20M$2.47M$2.62M$2.63M$2.86M$3.11M$3.21M
Total assets$321.62M$348.13M$137.68M$169.43M$190.02M$204.40M$155.40M$182.50M
Current liabilities$21.34M$19.56M$16.71M$18.38M$18.82M$14.85M$12.16M$14.91M
Total liabilities$34.19M$32.86M$30.43M$32.52M$33.36M$29.77M$27.43M$30.53M
Shareholders' equity$287.43M$315.27M$107.25M$136.91M$156.67M$174.63M$127.97M$151.97M
Shares outstanding103.95M103.48M64.15M63.59M62.99M62.07M50.23M50.00M
Cash flow statement
Operating cash flow-$26.44M-$32.50M-$29.89M-$20.47M-$20.14M-$20.77M-$23.36M-$23.95M
Capital expenditure$80,000$21,000$102,000$176,000$45,000$39,000$187,000$299,000
Free cash flow-$26.52M-$32.52M-$30.00M-$20.64M-$20.19M-$20.81M-$23.54M-$24.25M
Investing cash flow$114,000-$226.03M$54.90M$29.82M-$44.02M$19.98M$29.81M$29.70M
Financing cash flow$206,000$241.75M$300,000$2.77M$4.36M$69.93M$96,000$543,000
Depreciation & amortization$300,000$300,000$274,000$272,000$300,000$300,000$291,000$291,000
Stock-based compensation$4.92M$12.37M$3.82M$3.28M$3.69M$3.83M$3.51M$2.94M
Share buybacks$0———$0———

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.